0.00Open2.22Pre Close0 Volume0 Open Interest101.00Strike Price0.00Turnover1433.21%IV3.48%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry2.22Extrinsic Value100Contract SizeAmericanOptions Type0.9243Delta0.0973Gamma44.93Leverage Ratio-282.6746Theta0.0000Rho41.53Eff Leverage0.0001Vega
Merck & Co Stock Discussion
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet